focus -WSS

focus

author：fashion 2025-09-06 02:16:31 - browse：1294

Matts Take Column Illustration — Molly Ferguson for STAT

The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly expanded use of the drug and medicines like it, known as GLP-1 medicines.

That could have a big, positive impact on public health, and it will very likely swell the coffers of the pharmaceutical companies that make these medicines, including Wegovy’s maker, Novo Nordisk, and Eli Lilly, now the most valuable drug company in history thanks largely to hopes for its GLP-1, Mounjaro. These are medicines that could save lives, make money, and perhaps reshape our culture. But they are also, we are learning, not without risk.

So what’s next?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Here's how to stay safe from wildfire smoke amid reduced air quality

Wikipedia

WSS

Illumina to lay off 10% of research and development team

Thousands protest in Iraq for a second day over burning of Quran in Sweden

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Supreme Court rules employers must be more accommodating of religious observance

Neuroscience’s long legacy of racism

Virtual Event: March of the Biosimilars

hotspot

focus

knowledge

Affirmative action in medical school literally saved lives

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

Alkermes shareholders re

5 to watch: Tech startups trying to solve health care's staffing crisis

Trump demands the U.S. pay no more for drugs than other countries … again

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Hollywood unions extend contract negotiations for actors

Baby aspirin cuts fat buildup in liver disease patients, in small study

Drug repurposing or repositioning? The language matters

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

focus

Baby aspirin cuts fat buildup in liver disease patients, in small study

Virtual Event: March of the Biosimilars

GOP inquiry over gain

Stop the failed accountable care organization experiment

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

focus

Wikipedia

hotspot

leisure time